Creative Planning acquired a new position in shares of Cryolife Inc (NYSE:CRY) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 7,706 shares of the medical equipment provider’s stock, valued at approximately $209,000.
Several other hedge funds also recently modified their holdings of CRY. Tower Research Capital LLC TRC increased its position in shares of Cryolife by 357.0% during the third quarter. Tower Research Capital LLC TRC now owns 2,285 shares of the medical equipment provider’s stock worth $62,000 after acquiring an additional 1,785 shares in the last quarter. Exchange Traded Concepts LLC acquired a new position in Cryolife during the fourth quarter worth $87,000. SG Americas Securities LLC acquired a new position in Cryolife during the fourth quarter worth $116,000. Mackay Shields LLC acquired a new position in Cryolife during the third quarter worth $279,000. Finally, Municipal Employees Retirement System of Michigan boosted its holdings in Cryolife by 10.9% during the third quarter. Municipal Employees Retirement System of Michigan now owns 11,250 shares of the medical equipment provider’s stock worth $305,000 after purchasing an additional 1,110 shares during the last quarter. 76.75% of the stock is owned by institutional investors.
Shares of CRY opened at $27.53 on Friday. Cryolife Inc has a 12 month low of $20.76 and a 12 month high of $33.00. The firm has a fifty day simple moving average of $29.08 and a 200 day simple moving average of $26.60. The stock has a market capitalization of $1.03 billion, a price-to-earnings ratio of 688.42, a PEG ratio of 43.91 and a beta of 0.67. The company has a current ratio of 5.03, a quick ratio of 3.82 and a debt-to-equity ratio of 0.83.
Cryolife (NYSE:CRY) last announced its earnings results on Thursday, February 13th. The medical equipment provider reported $0.10 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.07 by $0.03. The business had revenue of $69.70 million during the quarter, compared to analysts’ expectations of $72.95 million. Cryolife had a net margin of 0.62% and a return on equity of 4.19%. As a group, research analysts predict that Cryolife Inc will post 0.34 earnings per share for the current fiscal year.
CRY has been the subject of several recent research reports. Canaccord Genuity cut shares of Cryolife from a “buy” rating to a “hold” rating and reduced their target price for the stock from $32.00 to $29.00 in a report on Friday. First Analysis cut shares of Cryolife from a “strong-buy” rating to an “outperform” rating in a report on Friday. Zacks Investment Research cut shares of Cryolife from a “buy” rating to a “hold” rating in a report on Wednesday, October 23rd. Oppenheimer initiated coverage on shares of Cryolife in a report on Tuesday, October 22nd. They set an “outperform” rating and a $34.00 target price for the company. Finally, ValuEngine cut shares of Cryolife from a “buy” rating to a “hold” rating in a report on Saturday, January 4th. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. Cryolife presently has a consensus rating of “Buy” and a consensus target price of $32.00.
In other Cryolife news, VP Jean F. Holloway sold 8,458 shares of the stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $30.00, for a total value of $253,740.00. Following the completion of the sale, the vice president now owns 67,322 shares in the company, valued at $2,019,660. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, VP Scott B. Capps sold 7,184 shares of the stock in a transaction on Tuesday, November 26th. The shares were sold at an average price of $24.93, for a total transaction of $179,097.12. Following the completion of the sale, the vice president now owns 151,079 shares of the company’s stock, valued at approximately $3,766,399.47. The disclosure for this sale can be found here. In the last quarter, insiders sold 19,837 shares of company stock valued at $536,927. Corporate insiders own 4.40% of the company’s stock.
CryoLife, Inc, together with its subsidiaries, manufactures, processes, and distributes medical devices and implantable human tissues for use in cardiac and vascular surgeries worldwide. The company operates in two segments, Medical Devices and Preservation Services. It offers BioGlue, an agent for cross-linking proteins for cardiac, vascular, pulmonary, and general surgical applications; On-X mechanical heart valves for aortic and mitral indications; cardiac preservation services; PhotoFix, a bovine pericardial patch for use in cardiac and vascular repairing activities; and PerClot, an absorbable powdered hemostat for use in surgical procedures, including cardiac, vascular, orthopedic, neurological, gynecological, ENT, and trauma surgeries.
Further Reading: What is a Derivative?
Want to see what other hedge funds are holding CRY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cryolife Inc (NYSE:CRY).
Receive News & Ratings for Cryolife Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cryolife and related companies with MarketBeat.com's FREE daily email newsletter.